Ki Society Aikido (Vol 4): Advanced Defensive Techniques With Ken Ota | BlackBelt Magazine In this episode, step into the realm of Ki Society Aikido alongside Ken Ota. Presented by BlackBelt Magazine, ...

Elisabeth Hasselbeck is never going to tribal council again. The Survivor alum, 48, placed fourth on season 2 of the show in 2001, but recently revealed that fans of the competition series shouldn't ...

Elisabeth Hasselbeck returned to The View to offer her conservative voice at the table as Alyssa Farah Griffin is on maternity leave. Although Hasselbeck doesn’t have a problem going back to her ...

"They have," Hasselbeck confirmed, before explaining that she'll never go back to the show. "Solid no. Solid no, every single time." Teta pressed her on if they asked her to be part of the current ...

In December, Howard Marks published an investment memo titled, “Is it a bubble?” that expressed some of his skepticism and reservations about artificial intelligence and the stock-market boom it had ...

Molecular model of the tumor suppressor protein p53 (beige) bound to a molecule of DNA (red and blue). P53 maintains genomic stability by controlling cell division, repairing DNA damage, and ...

It’s the 30th anniversary of Section 230 of the Communications Decency Act, a law that says that communications platforms aren’t legally responsible for what users post. That means this law is older ...

Let’s talk about Donut Lab’s solid-state batteries. When a company claims to have created what’s essentially the holy grail of batteries, there are bound to be some questions. Interest has been ...

The world’s first solid-state battery, announced by Donut Lab, has sparked interest for its potential advancements over traditional lithium-ion technology. While marketed as a breakthrough in energy ...

The Finnish startup’s pack can charge from 0 to 80 percent in under 5 minutes, according to its first independent test. The Finnish startup’s pack can charge from 0 to 80 percent in under 5 minutes, ...

Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 patients with advanced disease. The pharma giant halted the phase 1 trial of QEQ278 ...